UNSPSC 51111648: Oteracil

This classification denotes a pyrimidine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5VT6420TIG. European Medicines Agency schedules Oteracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30899. Oteracil generally arises in the molecular formula C4H3N3O4. The term OTERACIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule oteracil under HS 29336980 and SITC 51576.

As of Q4 2014, OTERACIL remains the US FDA Preferred Term for this commodity. Oteracil bears US NLM identifiers UMLS ID C0030032 and NCI Concept Code C76917. SMILES: C1(=NC(=O)NC(=O)N1)C(=O)[O-].[K+].

UNSPSC 51111648 Oteracil is a Commodity code representing pharmaceutical products purchased directly by state health and human services agencies. The code captures state procurement of specific medications—in this case, oteracil, a pharmaceutical treatment—typically sourced through state pharmacy benefit programs, Medicaid agencies, and health plan administrators that negotiate pricing and supply arrangements with manufacturers and wholesalers. State and local governments procure under this code primarily through their Medicaid or employee health benefit programs, with state health and human services commissions serving as the primary issuing bodies. These agencies manage procurement both for direct-to-consumer dispensing and for institutional use within state health systems, and they increasingly explore direct relationships with manufacturers to optimize cost and supply efficiency outside traditional pharmacy benefit manager intermediaries.

Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI, issued as an exploratory procurement mechanism ahead of a formal RFP, solicits vendor experience with direct contracting for self-insured employers and state health plans, flexibility to negotiate net-pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The RFI represents early-stage market intelligence gathering rather than a competitive solicitation with binding timelines, award amounts, or set-asides. No other recent state or local opportunities under this code appear in the source material, suggesting limited current activity at the state and local level for this specific pharmaceutical commodity.